Why this stock is getting sudden spike in the volume and the price. Please read below.
About the company
OncoSec Medical Incorporated is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers. The Company’s acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
What's the catalyst for this Spike
SAN DIEGO, Oct. 09, 2012 /PRNewswire/ -- OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced the company will be presenting data at two upcoming medical conferences.
Dr. Shailender Bhatia, assistant professor at the University of Washington School of Medicine, will be presenting preliminary clinical data from OncoSec's ongoing Phase II Merkel cell carcinoma trial at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2012), October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.
The company will also be presenting preliminary clinical data from its ongoing Phase II metastatic melanoma trial to the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress, November 14-17, 2012, at the Hotel Fira Palace in Barcelona, Spain.
Preliminary analyses of both the Merkel cell carcinoma and metastatic melanoma trials will be based on a subset of enrolled subjects, and will evaluate clinical response to at least one cycle of ImmunoPulse treatment.
At the Melanoma/EADO meeting on November 15 at 5:30 PM local Barcelona time, Adil I. Daud, M.D., co-director of melanoma clinical research at the University of California San Francisco's Helen Diller Family Comprehensive Cancer Center and lead investigator for OncoSec's metastatic melanoma trial, along with Axel Hauschild, M.D., professor of dermatology at the University of Kiel, will co-chair an OncoSec-sponsored symposium titled "Electrogenetherapy: Intralesional Immunotherapy Approach for Skin Cancers Using Electroporation."
The company will provide a complete summary of the data presented at both conferences in upcoming press releases.
My Take on the Share price and action for rest of the week
Company CEO completed his presentation in Swiss Stock exchange.. See the tweet below
Presented at the Swiss Stock Exchange today. Next up, London Stock Exchange & NYSE EuroNext Paris! #invescore2012 $ONCSpic.twitter.com/fPrRXeRH
With lots of interest and the volume spike I see this closing @ or above 50 cents for the week with ease
2. PURE - Closing Price @ 1.26 on 10/10
This is a pure bottom bounce play closing @ 1.26 with the next resistance @ 1.75, which it will target for this week . Please see the chart below
http://stockcharts.com/h-sc/ui?s=pure
This stock is a perfect example of text book trading.. So play the dips and get ur 20% gains for this week
Happy Trading All ................... Adious
No comments:
Post a Comment